ギンコ・バイオワークス・ホールディングスの掲示板の投稿コメント詳細

Excluding the $45 million non-cash deferred revenue release, third quarter 2024 Cell Engineering revenue of $30 million, down from $37 million in the comparable prior year period, a decrease of 20% driven by the continued shift from early stage customers to large/enterprise customers along with commercial changes related to the restructuring

Third quarter 2024 Biosecurity revenue of $14 million with gross profit margin of 28%. Biosecurity revenue decreased from the comparable prior year period due to the expected ramp down of K-12 testing

↑肝心のビジネスはこんな感じ。メッタメタ。焼野原。ここから事業整理したらさらに売り上げ落ちて墜落します。